Susquehanna International Group’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $107K | Buy |
49,085
+10,567
| +27% | +$26.2K | ﹤0.01% | 12301 |
|
|
2025
Q4 | $69.3K | Sell |
38,518
-34,404
| -47% | -$70.3K | ﹤0.01% | 11632 |
|
|
2025
Q3 | $162K | Sell |
72,922
-225,645
| -76% | -$367K | ﹤0.01% | 11210 |
|
|
2025
Q2 | $442K | Sell |
298,567
-560,083
| -65% | -$1.15M | ﹤0.01% | 9460 |
|
|
2025
Q1 | $2.2M | Buy |
+858,650
| New | +$2.05M | ﹤0.01% | 5309 |
|
|
2024
Q4 | – | Sell |
-70,817
| Closed | -$72.2K | – | 12984 |
|
|
2024
Q3 | $72.2K | Sell |
70,817
-87,430
| -55% | -$91.9K | ﹤0.01% | 11220 |
|
|
2024
Q2 | $185K | Buy |
158,247
+82,129
| +108% | +$97K | ﹤0.01% | 10474 |
|
|
2024
Q1 | $95.9K | Sell |
76,118
-27,132
| -26% | -$40.5K | ﹤0.01% | 11244 |
|
|
2023
Q4 | $184K | Buy |
+103,250
| New | +$161K | ﹤0.01% | 10766 |
|
|
2023
Q3 | – | Sell |
-15,864
| Closed | -$28.5K | – | 12742 |
|
|
2023
Q2 | $31.7K | Buy |
+15,864
| New | +$37.8K | ﹤0.01% | 11495 |
|
|
2022
Q4 | – | Sell |
-222,261
| Closed | -$244K | – | 13387 |
|
|
2022
Q3 | $231K | Buy |
+222,261
| New | +$246K | ﹤0.01% | 10475 |
|
|
2022
Q2 | – | Sell |
-12,119
| Closed | -$14.2K | – | 13697 |
|
|
2022
Q1 | $13K | Sell |
12,119
-69,831
| -85% | -$64K | ﹤0.01% | 12717 |
|
|
2021
Q4 | $68K | Sell |
81,950
-169,221
| -67% | -$177K | ﹤0.01% | 12398 |
|
|
2021
Q3 | $334K | Sell |
251,171
-31,974
| -11% | -$48.6K | ﹤0.01% | 10344 |
|
|
2021
Q2 | $541K | Buy |
283,145
+79,332
| +39% | +$273K | ﹤0.01% | 9395 |
|
|
2021
Q1 | $909K | Buy |
203,813
+148,224
| +267% | +$690K | ﹤0.01% | 7986 |
|
|
2020
Q4 | $202K | Buy |
+55,589
| New | +$199K | ﹤0.01% | 10024 |
|
|
2019
Q4 | – | Sell |
-3,121
| Closed | -$6K | – | 10415 |
|
|
2019
Q3 | $6K | Buy |
+3,121
| New | +$9.31K | ﹤0.01% | 10040 |
|
|
2019
Q2 | – | Sell |
-10,382
| Closed | -$43.9K | – | 10685 |
|
|
2019
Q1 | $46K | Sell |
10,382
-2,466
| -19% | -$11.1K | ﹤0.01% | 8480 |
|
|
2018
Q4 | $40K | Buy |
12,848
+2,282
| +22% | +$10.8K | ﹤0.01% | 8549 |
|
|
2018
Q3 | $77K | Buy |
10,566
+7,610
| +257% | +$38.2K | ﹤0.01% | 8700 |
|
|
2018
Q2 | $13K | Sell |
2,956
-8,083
| -73% | -$35.9K | ﹤0.01% | 9457 |
|
|
2018
Q1 | $60K | Buy |
11,039
+8,428
| +323% | +$55.4K | ﹤0.01% | 8906 |
|
|
2017
Q4 | $17K | Buy |
2,611
+532
| +26% | +$3.59K | ﹤0.01% | 9085 |
|
|
2017
Q3 | $12K | Sell |
2,079
-5,692
| -73% | -$36.5K | ﹤0.01% | 8682 |
|
|
2017
Q2 | $65K | Buy |
7,771
+811
| +12% | +$7.61K | ﹤0.01% | 8833 |
|
|
2017
Q1 | $95K | Buy |
6,960
+3,186
| +84% | +$28.6K | ﹤0.01% | 8411 |
|
|
2016
Q4 | $17K | Buy |
3,774
+2,726
| +260% | +$12.2K | ﹤0.01% | 9444 |
|
|
2016
Q3 | $6K | Buy |
+1,048
| New | +$6.54K | ﹤0.01% | 8302 |
|
|
2015
Q4 | – | Sell |
-1,260
| Closed | -$12.8K | – | 9841 |
|
|
2015
Q3 | $15K | Buy |
+1,260
| New | +$20K | ﹤0.01% | 9520 |
|
|
2015
Q2 | – | Sell |
-1,546
| Closed | -$32.1K | – | 10365 |
|
|
2015
Q1 | $28K | Sell |
1,546
-4,267
| -73% | -$83.5K | ﹤0.01% | 9238 |
|
|
2014
Q4 | $107K | Sell |
5,813
-3,989
| -41% | -$85.7K | ﹤0.01% | 9165 |
|
|
2014
Q3 | $237K | Sell |
9,802
-7,615
| -44% | -$219K | ﹤0.01% | 8391 |
|
|
2014
Q2 | $636K | Sell |
17,417
-1,074
| -6% | -$43.3K | ﹤0.01% | 7006 |
|
|
2014
Q1 | $847K | Sell |
18,491
-7,676
| -29% | -$358K | ﹤0.01% | 5799 |
|
|
2013
Q4 | $1.02M | Buy |
26,167
+535
| +2% | +$22.5K | ﹤0.01% | 5476 |
|
|
2013
Q3 | $1.16M | Buy |
+25,632
| New | +$1.32M | ﹤0.01% | 5023 |
|
Other funds holding PLX
MCO
SWP
VPM
PFS
OM
Susquehanna International Group's PLX Position: Q1 2026 in Review
Susquehanna International Group increased its Protalix BioTherapeutics (PLX) stake by 27% in Q1 2026, buying an estimated $26.2K and bringing the position to 49,085 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #12301.
Susquehanna International Group first reported a position in PLX in Q3 2013 and has held it in 37 quarters since. The position peaked at $2.2M in Q1 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.
- Susquehanna International Group held 49,085 shares of Protalix BioTherapeutics worth $107K as of Q1 2026.
- Susquehanna International Group bought 10,567 Protalix BioTherapeutics shares in Q1 2026, an estimated $26.2K.
- Protalix BioTherapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12301 holding.
- Susquehanna International Group first reported a position in Protalix BioTherapeutics in Q3 2013 and has held it in 37 quarters since.
- Susquehanna International Group's Protalix BioTherapeutics position peaked at $2.2M in Q1 2025.
- 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.